Latest Litigation Risk News

Acusensus Limited has successfully raised $30 million through a placement of 20 million shares at $1.50 each, supported by both existing and new investors. The capital injection aims to fuel business development, product innovation, and operational expansion.

Lifestyle Communities is extending an option for existing homeowners to adopt a revised Deferred Management Fee model following a pivotal VCAT ruling, aiming to enhance transparency and goodwill regardless of the appeal outcome.

Identitii Limited has announced a pro rata non-renounceable rights issue to raise approximately $2.88 million, partially underwritten by Beauvais Capital Pty Ltd. The funds will support the development and commercialisation of its BNDRY platform amid ongoing patent litigation risks.

ResMed Inc. reported a robust 9% increase in net revenue for Q1 FY2026, driven by strong demand in its Sleep and Breathing Health and Residential Care Software segments. Despite ongoing patent litigation, the company delivered a 12% rise in net income and boosted shareholder returns with a $150 million share repurchase.

Ovanti Limited has made significant strides in its U.S. buy now, pay later (BNPL) expansion, securing a major partnership with Shift4 Payments and raising $8 million to fuel growth.

Renergen Limited reports significant progress on its merger with ASP Isotopes, resolves a key dispute with Springbok Solar, and reveals promising exploration developments, while managing production and financial challenges.

The National Court of Papua New Guinea has dismissed litigation brought by offshore-funded landowners against Bougainville Copper Limited, ordering indemnity costs in the company’s favor.

Mayne Pharma reported a 5% revenue increase to $408.1 million for FY25 but posted a net loss of $93.8 million, narrowing from the prior year. The company’s planned acquisition by Cosette Pharmaceuticals faces legal hurdles, delaying completion.

Acusensus Limited reported a 20% increase in revenue to $59.35 million for FY25, driven by new and expanded contracts across Australia, New Zealand, the US, and the UK. However, net losses widened by 72.3%, reflecting higher operating expenses and ongoing litigation costs.

Transurban reports solid FY25 financial results with strong EBITDA and free cash flow growth, steady operating costs, and promising progress on NSW Toll Reform and major infrastructure projects.

ResMed Inc. reported a robust 10% increase in revenue to $5.15 billion for fiscal 2025, driven by strong demand in sleep and breathing health devices and residential care software. The company also expanded its diagnostic capabilities with the acquisition of VirtuOx, positioning itself for further growth in home-based health solutions.

Power Minerals Limited has launched a new options offer linked to a recent $1.3 million placement, alongside updates on key project acquisitions and divestments. The prospectus outlines significant risks and strategic directions as the company navigates growth and financial challenges.